Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62,955 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).
Kim JY, Park S, Im SA, Kim SB, Sohn J, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH, Park YH; Korean Cancer Study Group. Kim JY, et al. Among authors: park ih, park yh, park s. Cancer Commun (Lond). 2019 May 28;39(1):29. doi: 10.1186/s40880-019-0375-7. Cancer Commun (Lond). 2019. PMID: 31138332 Free PMC article. Clinical Trial.
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
Park YH, Lal S, Lee JE, Choi YL, Wen J, Ram S, Ding Y, Lee SH, Powell E, Lee SK, Yu JH, Ching KA, Nam JY, Kim SW, Nam SJ, Kim JY, Cho SY, Park S, Kim J, Hwang S, Kim YJ, Bonato V, Fernandez D, Deng S, Wang S, Shin H, Kang ES, Park WY, Rejto PA, Bienkowska J, Kan Z. Park YH, et al. Among authors: park s, park wy. Nat Commun. 2020 Dec 2;11(1):6175. doi: 10.1038/s41467-020-19933-0. Nat Commun. 2020. PMID: 33268821 Free PMC article.
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Tan RSYC, Ong WS, Lee KH, Lim AH, Park S, Park YH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Ryu HS, Han W, Tan VKM, Wong FY, Im SA, Tan PH, Chan JY, Yap YS. Tan RSYC, et al. Among authors: park yh, park s. BMC Med. 2022 Mar 17;20(1):105. doi: 10.1186/s12916-022-02284-6. BMC Med. 2022. PMID: 35296300 Free PMC article.
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Park YH, Im SA, Park K, Wen J, Lee KH, Choi YL, Lee WC, Min A, Bonato V, Park S, Ram S, Lee DW, Kim JY, Lee SK, Lee WW, Lee J, Kim M, Kim HS, Weinrich SL, Ryu HS, Kim TY, Dann S, Kim YJ, Fernandez DR, Koh J, Wang S, Park SY, Deng S, Powell E, Ravi RK, Bienkowska J, Rejto PA, Park WY, Kan Z. Park YH, et al. Among authors: park s, park sy, park k, park wy. Genome Med. 2023 Jul 20;15(1):55. doi: 10.1186/s13073-023-01201-7. Genome Med. 2023. PMID: 37475004 Free PMC article.
62,955 results
You have reached the last available page of results. Please see the User Guide for more information.